Bio Path Holdings Inc (BPTH)

[SJSTOCKSHARK]

The news is on page 8 under number 8:

8. Subsequent Events

Bio-Path entered into an agreement for drug substance manufacture of development batches of the antisense material for its second drug candidate, Liposomal Bcl-2. The Company also entered into an agreement with a testing firm for a new drug substance characterization assay. Bio-Path entered into an agreement with a public relations firm for development and execution of a communications program designed to increase visibility and understanding of, as well as interest in, Bio-Path, its product candidates, business strategy, milestones and people among key stakeholders. In total, these projects will require Bio-Path to pay approximately $200,000 over a twelve month period.

We have a new PR firm!

We are starting to manufacture antisense material for our second drug....Bcl-2.

A new assay testing agreement. See page 17 first paragraph for the purpose of the new assay.

BP1001 to enter phase I trial for TNBC and IBC in late 2015. See the last paragraph of page 20.

Breast cancer is the Holy Grail for this company.